1、TandutinibCat. No.: HY-10202CAS No.: 387867-13-2分式: CHNO分量: 562.7作靶点: FLT3作通路: Protein Tyrosine Kinase/RTK储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 36 mg/mL (63.98 mM)* “ means soluble, but saturation unknown.ConcentrationSolvent Mass 1 mg 5 mg 10 mg1 mM
2、1.7771 mL 8.8857 mL 17.7715 mL5 mM 0.3554 mL 1.7771 mL 3.5543 mL制备储备液10 mM 0.1777 mL 0.8886 mL 1.7771 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液体内实验 Tandutinib is prepared in PBS4.1. BIOLOGICAL ACTIVITY物活性 Tandutinib（MLN518, CT53518） 是 FLT3拮抗剂， IC50为0.22 M，还抑制 PDGFR 和 c-Kit。客户使本产品发表的科研献See more customer validat
3、ions on www.MedChemEProduct Data Sheet InhibitorsAgonistsScreening Libraries Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Drug Des Devel Ther. 2018 Apr 30;12:1009-1017. Biochem Biophys Res Commun. 2017 Aug 19;490(2):209-216.www.MedChemE1REFERENCES1. Kelly LM, et al. CT53518, a novel selective
4、 FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432.2. Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104(9), 2912-2918.3. Schittenhelm MM, et al. The FLT3 inhibitor tandut
5、inib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle, 2009, 8(16), 2621-2630.4. Salama Y, et al. The angiogenic factor Egfl7 alters thymogenesis by activating Flt3 signaling. Biochem Biophys Res Commun. 2017 Aug 19;490(2):209-216.McePdfHeightCaution: Product has not been fully validated for medical applications. For research use only.Tel: 400-820-3792; 021-58955995 Fax: 021-53700325 E-mail: techMedChemEMaster of Small Molecules 您边的抑制剂师www.MedChemE2
